Summary of Key Points from the Conference Call Industry Overview - The conference call primarily discusses the dynamics of inflation in China and its implications for various sectors, particularly in the context of geopolitical tensions and oil prices [1][5][8]. Core Insights and Arguments 1. **Inflation Dynamics in China**: - China is currently in a reflation journey, but demand remains the missing engine for sustainable growth [5][6]. - The GDP deflator has stepped out of deflation but is not fully recovered, indicating ongoing economic challenges [6][7]. 2. **Investment Trends**: - Investment in oversupplied sectors has slowed, but there is no significant slump observed [6]. - Existing excess capacity is being cut through production curbs, although durable capacity closures are not yet evident [6]. 3. **Oil Price Scenarios**: - Three scenarios for oil prices were outlined: - **Scenario 1 (Normalization)**: Oil prices expected to be between US$80-90 per barrel in 2026, returning to US$75 thereafter. - **Scenario 2 (Ongoing Constraints)**: Oil prices projected at US$100-110 per barrel in 2026, returning to US$80 later. - **Scenario 3 (Effective Closure)**: Oil prices could spike to US$150-180 per barrel before normalizing [3][4]. 4. **Corporate Margins**: - Shifts in upstream inflation directly affect upstream profit margins, while downstream margins depend on whether inflation is cost-push or demand-pull [16][18]. - The profit rebound in industrial sectors is supported by volume increases, with selective sectors showing significant profit growth [21][25]. 5. **Sector-Specific Performance**: - Industrial profits have rebounded, particularly in sectors such as automobiles and pharmaceuticals, while other sectors like coal and non-ferrous metals are lagging [27][25]. Additional Important Insights - **Social Security and Long-term Care Insurance**: - The contribution breakdown for long-term care insurance indicates a significant reliance on individual contributions (55%) and corporate contributions (34%) [29]. - The average annual subsidy per pensioner shows a fragmented social welfare system with wide benefit gaps across social groups [31][33]. - **Geopolitical Tensions**: - The call also touched on the impact of geopolitical tensions on market dynamics, particularly regarding oil supply routes and pricing [2][3]. This summary encapsulates the critical insights from the conference call, highlighting the current economic landscape in China, the implications of oil price fluctuations, and the performance of various industrial sectors.

Core Insights - Crescita Therapeutics reported its financial results for Q4 and fiscal year 2025, highlighting a decline in revenue for Q4 but an overall increase for the fiscal year, driven by successful asset integration and strategic acquisitions [1][4][5]. Financial Highlights Q4-2025 vs. Q4-2024 - Revenue decreased to $5,955 from $6,902, a decline of $947, primarily due to a reimbursement for unused inventory [5][17]. - Gross profit increased to $3,239 from $2,807, up $432, resulting in a gross margin of 54.4% compared to 40.7% [5][19]. - Operating expenses rose to $3,620 from $3,075, an increase of $545, mainly due to higher selling, general, and administrative expenses [5][22]. - Net loss widened to $(711) from $(162), an increase of $549 [5][14]. - Adjusted EBITDA decreased to $70 from $151, down $81 [5][14]. F2025 vs. F2024 - Total revenue for the fiscal year increased to $21,118 from $19,580, an increase of $1,538, attributed to higher skincare revenue and the impact of acquisitions [5][18]. - Gross profit rose to $11,109 from $8,990, up $2,119, with a gross margin of 52.6% compared to 45.9% [5][21]. - Operating expenses slightly decreased to $12,131 from $12,205, a reduction of $74 [5][23]. - Net loss improved to $(92) from $(2,750), a significant reduction of $2,658 [5][14]. - Adjusted EBITDA increased to $617 from $(1,541), an improvement of $2,158 [5][14]. Operational and Corporate Developments - Crescita announced a proposed acquisition by ClinActiv Holdings at a cash consideration of $0.80 per share, representing a 74% premium over the five-day volume weighted average price [6][7]. - The acquisition is expected to close in Q2 2026, subject to shareholder and court approvals [7][8]. - The company renewed its lease for its manufacturing and office facility for an additional five years [8]. - Crescita acquired assets from Laboratoire Provence-Canada Inc. for $775, enhancing its manufacturing capabilities [8]. - A mutual termination of the licensing agreement with Croma Pharma for Pliaglis® resulted in a termination payment of €575,000 (CA$902,000) [8].

Market Performance - The Tel Aviv Stock Exchange experienced a significant decline, with the Tel Aviv 35 Index dropping 1.89% to 4,022.57 points, and the Tel Aviv 125 Index falling 1.98% to 3,941.78 points [1] - The BlueTech Global Index decreased by 1.52% to 659.59 points, while the All Bond corporate bond index fell 0.16% to 419.30 points [1] - Total turnover in equities reached NIS 7.49 billion, and in bonds, it totaled NIS 11.66 billion [1] Currency Exchange Rates - The shekel-dollar exchange rate was set 0.667% higher at NIS 3.170/$, while the shekel-euro rate increased by 0.389% to NIS 3.642/€ [2] Banking Sector Performance - Bank Leumi led the market decline, falling 4.09% with the highest trading turnover, followed by Bank Hapoalim which dropped 4.53% [3] - Mizrahi Tefahot Bank decreased by 2.23%, Israel Discount Bank fell 2.70%, and First International Bank of Israel saw a decline of 4.70% [3] Other Notable Stocks - Tower Semiconductor Ltd. fell 2.05%, and Elbit Systems Ltd. decreased by 2% [4] - Teva Pharmaceutical Industries Ltd. experienced a decline of 1.30%, while Next Vision fell 2.32% [4] - ICL saw the largest increase on the Tel Aviv 35 Index, rising by 3.07%, followed by Delek Group with a rise of 0.96% and Ormat Technologies Inc. increasing by 2.65% [4]

Core Insights - Incyte announced positive 54-week data for povorcitinib, a JAK1 inhibitor, in treating moderate to severe hidradenitis suppurativa (HS) at the 2026 AAD Annual Meeting, highlighting its potential as a first oral treatment option for HS [1][11]. Group 1: Clinical Efficacy - The 54-week results from the STOP-HS program showed that up to 71.4% of patients achieved HiSCR50, with 57% achieving HiSCR75 and 29% achieving HiSCR100, indicating substantial and durable clinical efficacy [4][6]. - Clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54, with 40.5-46.8% of participants reporting improvements in skin pain and 49.0-58.0% in fatigue [8][9]. - Full resolution of inflammatory lesions was achieved in up to 20% of patients, with consistent reductions in abscesses, inflammatory nodules, and draining tunnels across both doses [7][4]. Group 2: Safety Profile - The overall safety profile of povorcitinib through 54 weeks was consistent with previously reported data, with treatment-emergent adverse events (TEAEs) occurring in 76.2% to 83.4% of patients, primarily mild or moderate [9][10]. - Serious TEAEs were low, ranging from 3.7% to 6.4%, and grade >3 TEAEs were reported at 5.4% to 8.0%, indicating a manageable safety profile [9][10]. - Rates of adverse events of special interest, including serious infections and malignancies, were low (<2.3%), supporting the safety of povorcitinib [10]. Group 3: Regulatory and Market Implications - The STOP-HS data support the submission of a New Drug Application (NDA) and Marketing Authorization Application (MAA) for povorcitinib, which are currently under review by the U.S. FDA and European Medicines Agency [11][18]. - Incyte aims to advance regulatory applications in the U.S. and Europe, indicating a strategic focus on expanding its market presence in the treatment of HS [3][11].

Core Insights - Corcept Therapeutics presented data from the MOMENTUM trial, revealing that 27.3% of patients with resistant hypertension have hypercortisolism, indicating a significant prevalence of this condition in a challenging patient population [1][2][3] Group 1: MOMENTUM Trial Findings - The MOMENTUM trial screened 1,086 patients with resistant hypertension, identifying hypercortisolism in 297 patients, which is 27.3% of the total [2][5] - The trial's findings align with the CATALYST trial, which reported hypercortisolism in 23.8% of 1,057 patients with difficult-to-control type 2 diabetes [2] - Among patients with hemoglobin A1c (HbA1c) of 7.5% or higher taking three or more blood pressure medications, the prevalence of hypercortisolism was 32.6% in MOMENTUM and 36.6% in CATALYST [2] Group 2: Clinical Implications - Resistant hypertension is associated with increased risks of cardiovascular events, including heart attacks and strokes, as well as kidney damage [3] - The data suggests that screening for hypercortisolism in patients with resistant hypertension could lead to more personalized treatment approaches [3][4] - Corcept's Chief Development Officer emphasized the need for increased screening and improved treatment options based on the trial's findings [4] Group 3: Company Overview - Corcept Therapeutics focuses on cortisol modulation to treat various serious disorders and has developed over 1,000 proprietary selective cortisol modulators [8] - The company has introduced Korlym®, the first FDA-approved medication for endogenous Cushing's syndrome, and Lifyorli™, a selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer [8]

Core Viewpoint - Lantern Pharma and Starlight Therapeutics have received FDA clearance for an Investigational New Drug (IND) application for STAR-001, which will be evaluated in a Phase 1 pediatric clinical trial targeting relapsed or refractory central nervous system (CNS) malignancies in children [1][4]. Group 1: Trial Overview - The planned multicenter Phase 1 trial will assess STAR-001 as a monotherapy and in combination with spironolactone in pediatric patients with various CNS malignancies, including ATRT, DIPG, GBM, medulloblastoma, and ependymoma [1][2][3]. - The trial will be conducted in collaboration with the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC), involving 14 leading academic children's cancer centers across the U.S., Canada, and Israel [3][14]. Group 2: Unmet Medical Need - Pediatric CNS tumors are a significant cause of cancer-related deaths among children and adolescents, with an estimated 4,975 new cases of primary brain tumors expected in the U.S. in 2026 [4]. - Globally, around 47,600 new pediatric CNS tumor cases are diagnosed annually, leading to approximately 23,500 deaths [4]. Group 3: Current Treatment Landscape - Despite advancements in treatment, survival rates for children with relapsed or refractory high-grade CNS tumors have seen only marginal improvements, with certain conditions like DIPG having a median survival of less than 12 months [5]. - Current therapeutic options for relapsed ATRT, GBM, medulloblastoma, and ependymoma are limited and often result in severe long-term toxicity [5]. Group 4: STAR-001 Mechanism and Efficacy - STAR-001 is a precision oncology compound identified through Lantern's RADR® AI platform, designed to target high-grade CNS tumors by exploiting the overexpression of PTGR1 [2][15]. - Preclinical studies indicate that the combination of STAR-001 and spironolactone can significantly enhance survival rates in ATRT models, extending median survival by 181% compared to control [7][10]. Group 5: Future Directions - The trial aims to enroll approximately 18 to 42 pediatric patients aged 1 to 17 years, subject to obtaining additional funding [14]. - The collaboration with POETIC provides a robust clinical infrastructure to reach a diverse patient population across North America and internationally [14].

Core Insights - Simulations Plus, Inc. will report its second quarter fiscal year 2026 financial results on April 9, 2026, after market close [1] - A conference call to discuss the results will take place on the same day at 5:00 p.m. ET, with participation options available for investors [2] Company Overview - Simulations Plus is recognized as a global leader in model-informed and AI-accelerated drug development, focusing on enhancing biopharma innovation [3] - The company aims to create value for clients by accelerating the discovery, development, and commercialization of pharmaceuticals through innovative software and consulting solutions [3]

Core Viewpoint - Poxel SA has confirmed the drawdown of €3.75 million under the Additional Tranche D PDR bond issue as part of its continuation plan approved by the Lyon Commercial Court on January 22, 2026 [1] Financing Details - Poxel has previously issued €0.5 million of Tranche D PDR bonds on February 16, 2026, and plans to issue an additional €0.5 million on March 26, 2026 [2] - The Tranche D PDR is a result of a contractual amendment to the IPF bond financing initiated in September 2024, aimed at securing the company's operations [3] - The financing aims to cover the company's operational costs and liabilities during the continuation plan, alongside other financing operations and cost reductions [5] Key Terms of Tranche D PDR - The cash interest rate for Tranche D PDR is set at 0%, with a capitalized interest rate of 35% and a commitment fee of 10% [7] - An exit fee of 13.7% is applicable, calculated based on the total amount of bonds issued [7] - The allocation rate of Twymeeg royalties for the repayment of the IPF bond financing is set at 90% [7] - The issuance of share subscription warrants is planned for Poxel's next general meeting [4] Company Overview - Poxel SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for chronic diseases with metabolic pathophysiology, including MASH and rare metabolic disorders [5] - The company’s product PXL065 has met its primary endpoint in a Phase 2 trial for MASH, while PXL770 is being developed for rare diseases [5] - Poxel's first-in-class product, TWYMEEG® (Imeglimin), is marketed in Japan for type 2 diabetes, with expected royalties and sales-based payments [5]

Core Viewpoint - Incyte has announced new executive leadership appointments to enhance its strategic focus and long-term growth plans, reflecting the company's commitment to innovation and operational effectiveness [1][5]. Leadership Appointments - Pablo J. Cagnoni, M.D. has been appointed as President and Global Head of Research and Development, continuing his responsibility for R&D while enhancing strategic planning and operational execution [2]. - Steven Stein, M.D. has been appointed Executive Vice President and Chief Medical Officer, overseeing late-stage development programs across Hematology, Oncology, and Immunology, as well as Global Medical Affairs [3]. - Mohamed Issa, Pharm.D. has been appointed Executive Vice President and Head of U.S. Commercial, integrating U.S. Oncology and Immunology into a single commercial organization to improve operational effectiveness [4]. Strategic Integration - The integration of U.S. commercial teams is aimed at driving effective launch execution and positioning Incyte for long-term success, as stated by CEO Bill Meury [5].

Core Insights - The collaboration between NetraMark Holdings Inc. and Fondazione per la Medicina Personalizzata (FMP) aims to analyze the ROME Phase II oncology trial dataset using NetraMark's NetraAI platform to identify clinically actionable insights for precision oncology strategies [1][5][7] Group 1: Collaboration Details - NetraMark will utilize its proprietary NetraAI platform to analyze the ROME dataset and other oncology datasets provided by FMP, focusing on uncovering clinically meaningful patient subpopulations and biomarker-driven treatment patterns [5][7] - The initial phase of the collaboration will concentrate on discovering and validating high-signal patient subgroups within the ROME dataset, with potential subsequent phases including tumor-specific analyses and evaluations of treatment modalities [6][7] Group 2: ROME Trial Overview - The ROME trial is a multicenter, randomized, open-label Phase II study that compares tailored treatment to standard care for patients with advanced solid tumors, guided by comprehensive genomic profiling [3][4] - In the intention-to-treat population of 400 randomized patients, the trial reported improvements in overall response rate and progression-free survival for tailored treatment compared to standard care, while overall survival was similar due to a high crossover rate [4] Group 3: Strategic and Clinical Value - The collaboration is expected to generate long-term value by combining FMP's oncology datasets with NetraAI's analytical capabilities, which may enhance future clinical trial design, biomarker development, and patient stratification strategies [7][8] - The goal is to identify Model-Derived Subgroups (MDS) that reveal underlying disease structures and treatment-response dynamics across key clinical endpoints [5][6] Group 4: NetraAI Technology - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, potentially increasing the likelihood of clinical trial success by avoiding overfitting and deriving actionable insights [10][11] - The platform's unique focus mechanisms allow for accurate segmentation of patient data, enhancing the ability to classify patients based on sensitivity to drugs and treatment efficacy [11]